Ovid Therapeutics (OVID) Accumulated Depreciation & Amortization (2020 - 2025)
Ovid Therapeutics (OVID) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $256000.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Accumulated Depreciation & Amortization fell 43.49% year-over-year to $256000.0, compared with a TTM value of $256000.0 through Sep 2025, down 43.49%, and an annual FY2024 reading of $613000.0, up 7.92% over the prior year.
- Accumulated Depreciation & Amortization was $256000.0 for Q3 2025 at Ovid Therapeutics, up from $240000.0 in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $613000.0 in Q4 2024 and bottomed at $73807.0 in Q1 2022.
- Average Accumulated Depreciation & Amortization over 5 years is $287616.6, with a median of $248000.0 recorded in 2025.
- The sharpest move saw Accumulated Depreciation & Amortization soared 116.17% in 2022, then plummeted 43.49% in 2025.
- Year by year, Accumulated Depreciation & Amortization stood at $237079.0 in 2021, then skyrocketed by 116.17% to $512505.0 in 2022, then grew by 10.83% to $568000.0 in 2023, then increased by 7.92% to $613000.0 in 2024, then tumbled by 58.24% to $256000.0 in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for OVID at $256000.0 in Q3 2025, $240000.0 in Q2 2025, and $141000.0 in Q1 2025.